X0202 SCHEDULE 13G/A 0001831942 XXXXXXXX LIVE 1 Common Stock, $0.001 par value 03/31/2026 0001750149 Inhibikase Therapeutics, Inc. 45719W205 1000 N. West Street Suite 1200 Wilmington DE 19801 Rule 13d-1(c) Commodore Capital LP DE 0.00 14054940.00 0.00 14054940.00 14054940.00 9.9 IA PN Commodore Capital Master LP E9 0.00 14054940.00 0.00 14054940.00 14054940.00 9.9 PN Robert Egen Atkinson X1 0.00 14054940.00 0.00 14054940.00 14054940.00 9.9 HC IN Michael Kramarz X1 0.00 14054940.00 0.00 14054940.00 14054940.00 9.9 HC IN Inhibikase Therapeutics, Inc. 1000 N. West Street, Suite 1200, Wilmington, DELAWARE, 19801. Commodore Capital LP Commodore Capital Master LP Robert Egen Atkinson Michael Kramarz Each a "Filer." The address for Commodore Capital LP, Robert Egen Atkinson, and Michael Kramarz is 444 Madison Avenue, Floor 35, New York, NY 10022. The address for Commodore Capital Master LP is c/o Maples Corporate Services Limited, Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands. See Item 4 of the cover page for each Filer. Y See Item 9 of the cover page for each Filer. This report on Schedule 13G is being filed by Commodore Capital LP (the "Firm"), Commodore Capital Master LP ("Commodore Master"), Michael Kramarz, and Robert Egen Atkinson. The Firm is the investment manager to Commodore Master. As of March 31, 2026, the Firm may be deemed to beneficially own an aggregate of 14,054,940 shares Common Stock, $0.001 par value (the "Common Stock"), consisting of (i) 5,397,488 shares of Common Stock (ii) Tranche 1 Warrants to purchase up to 5,290,799 shares of Common Stock (the "Tranche 1 Warrants"), and (iii) Tranche 2 Warrants to purchase up to 3,366,653 shares of Common Stock (the "Tranche 2 Warrants"), of Inhibikase Therapeutics, Inc. (the "Issuer"). The Tranche 1 Warrants and Tranche 2 Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation"). The foregoing excludes 6,362,736 shares of the Tranche 2 Warrants and 16,133,234 shares of Common Stock underlying a Pre-Funded Warrant, which are subject to the Beneficial Ownership Limitation. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 132,032,636 Common Stock reported as issued and outstanding as of March 31, 2026 in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026, plus (i) 5,290,799 Tranche 1 Warrants and (ii) 3,366,653 Tranche 2 Warrants. See Item 11 of the cover page for each Filer. See Item 5 of the cover page for each Filer. See Item 6 of the cover page for each Filer. See Item 7 of the cover page for each Filer. See Item 8 of the cover page for each Filer. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 1: Joint Filing Agreement Commodore Capital LP Michael Kramarz 05/15/2026 Commodore Capital Master LP Michael Kramarz 05/15/2026 Robert Egen Atkinson Robert Egen Atkinson 05/15/2026 Michael Kramarz Michael Kramarz 05/15/2026